drugset / Trial / NCT00870883
N-acetylcysteine Plus Deferoxamine for Patients With Hypotension
Phase 2
Completed
81 enrolled
Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude
Conselho Nacional de Desenvolvimento Científico e Tecnológico · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Oxidative stress is associated with kidney damage in several different situations, including hypotension. In animal models it has been shown that the combination of n-acetylcysteine plus deferoxamine is superior to its isolate use in the treatment of several diseases. Thus the investigators aimed to determine if the administration of n-acetylcysteine plus deferoxamine could prevent renal failure in critical ill patients who develops hypotension.
Timeline
- Start
- 2009-03
- Primary completion
- 2015-05
- Completion
- 2015-05
Publications
- Fraga CM, Tomasi CD, Damasio DC, Vuolo F, Ritter C, Dal-Pizzol F. N-acetylcysteine plus deferoxamine for patients with prolonged hypotension does not decrease acute kidney injury incidence: a double blind, randomized, placebo-controlled trial. Crit Care. 2016 Oct 17;20(1):331. doi: 10.1186/s13054-016-1504-1.
- Fraga CM, Tomasi CD, Biff D, Topanotti MF, Felisberto F, Vuolo F, Petronilho F, Dal-Pizzol F, Ritter C. The effects of N-acetylcysteine and deferoxamine on plasma cytokine and oxidative damage parameters in critically ill patients with prolonged hypotension: a randomized controlled trial. J Clin Pharmacol. 2012 Sep;52(9):1365-72. doi: 10.1177/0091270011418657. Epub 2011 Nov 1.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deferoxamine | Other / unclassified | 1000 mg | — |
| Subject | N-acetylcysteine | Small molecule | 100 mg/kg | Intravenous |